Elodie joined Novartis in August 2018 as Epidemiologist in Quantitative Safety and Epidemiology as part of Patient Safety. Leading pre- and post-marketing epidemiology strategy for several products in Respiratory, Global Health and Immunology, Hepatology & Dermatology (IHD). Elodie was a key contributor to internal initiative on Disease registries, and she is a member of CIOMS working group XIII on Real World Evidence. Before joining Novartis, Elodie was Associate Director, Epidemiology and Outcome Research, at Quintiles. She has 14 years of experience in pharmacoepidemiology within pharma companies and contract research organizations, where she worked in different therapeutic areas such as psychiatry, internal medicine, neurology, cardiology and others, and gained insight and expertise in designing, conducting and reporting observational studies. Elodie received MSc (focus on medicine and health products: impact on public health, market access, safety assessment) from CNAM, Conservatoire national des Arts et metiers, Paris, France, and holds a PharmD and MPH (focused on Methodology and Biostatistics) from University Paris XI, France.